ScripOpinions on Neurocrine Biosciences, Inc. ’s top-line Phase II data for schizophrenia candidate NBI-1117568 were anything but clear cut on 28 August, as the company expressed strong optimism about the
Pink SheetAI And FDA: A Risk-Based Approach And New Industry User Fees? The US Food and Drug Administration likely will need a risk-based approach to reviewing the artificial intelligence aspects of drug applic
ScripThe Pros And Cons Of Flying Solo With Ex-US Launches There is plenty of money to be made in the international markets for US biotechs, but deciding to go it alone or find a partner abroad remains a tr
ScripAbbVie Inc. chairman and CEO Richard Gonzalez laid out the company’s succession plan clearly during its fourth quarter 2023 earnings call on 2 February, but offered no indication that the transition